Alzheimer's disease

@article{Ballard2011AlzheimersD,
  title={Alzheimer's disease},
  author={Clive G Ballard and Serge Gauthier and Anne Corbett and Carol Brayne and Dag Aarsland and Emma Jones},
  journal={The Lancet},
  year={2011},
  volume={377},
  pages={1019-1031}
}
View on Elsevier
doi.org
1,427 Citations
Highly Influential Citations
43
Background Citations
360
Methods Citations
10
Results Citations
6

Tables from this paper

1,427 Citations

A Meta-Analysis Study on Alzheimer’s Disease

  • Psychology, Biology
    Journal of Bioscience & Biomedical Engineering
  • 2021
To gather and assess information on Alzheimer’s disease and its treatment from published studies to depict the overall treatment effect, a thorough understanding of the disease's natural history was able to develop appropriate trial designs and outcomes for the various stages of Alzheimer's disease.

The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review

Strategies to implement genomics into translational clinical research that will not only improve accuracy of dementia diagnosis, thus enabling more personalized treatment strategies, but may also speed up the discovery of novel drugs and interventions are outlined.

Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases

A review of β-amyloid neuroimaging in Alzheimer's disease

The main efforts of neuroimaging in AD in humans and in mouse models are summarized, with a specific focus on β-amyloid, and the potential of new applications and novel approaches are discussed.

Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies

This review summarises the current understanding of the underlying biology of AD, PDD and DLB and outlines the most recent drug candidates in advanced clinical trials.

Prevention strategies for Alzheimer’s disease

Primary prevention studies include studying those subjects with more risk factors for AD, such as older age, those with a positive family history of late onset AD, and those who are ApoE4 positive, designed to increase the probability of developing AD thereby decreasing the sample size or the duration of follow up.

The Epidemiology and Prevention of Alzheimer’s Disease and Projected Burden of Disease

State of the Science: Use of Biomarkers and Imaging in Diagnosis and Management of Alzheimer Disease

  • Deirdre Brett Fraller
  • Medicine
    The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
  • 2013
New techniques able to identify AD in its earliest stages, before the development of the cognitive impairment that allows clinical diagnosis, could enable treatment to begin before pathology is advanced, and discuss how they might be used in the diagnosis and management of AD.

Genetics of Alzheimer's Disease

The known genetics of early- and late-onset Alzheimer's disease are reviewed, including APOE, which is a complex disorder with environmental and genetic components leading to disease.

Dementia in Down's syndrome

...

References

SHOWING 1-10 OF 125 REFERENCES

Cholesterol as a risk factor for Alzheimer's disease – epidemiological evidence

This review aims at presenting current epidemiological data on serum cholesterol levels and dietary fat intake as risk factors for dementia/AD, and at discussing the reasons and significance of contradictions between various studies.

Imaging cerebral atrophy: normal ageing to Alzheimer's disease

New perspectives on Alzheimer's disease.

  • D. Price
  • Biology
    Annual review of neuroscience
  • 1986
Investigations of animal models that recapitulate certain features of AD should provide new insights into the nature, mechanisms, and consequences of cellular pathology of specific systems.

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Clinical criteria for the diagnosis of Alzheimer’s disease include insidious onset and progressive impairment of memory and other cognitive functions, and Alterations in transmitter-specific markers include forebrain cho-linergic systems and noradrenergic and somatostatinergic systems that innervate the telencephalon.

Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists.

The guidelines presented are adapted from those used by many neuropathologists at Alzheimer's disease research centers participating in CERAD, the Consortium to Establish a Registry for Alzheimer's Disease.

AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease

The development and design of AddNeuroMed and the progress toward the development of plasma markers show that plasma markers are feasible and animal models are valuable in biomarker research.

Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve

Using a normalized thickness index-based criterion may help with early diagnosis of Alzheimer's disease at the individual level, especially for highly educated subjects, up to 24 months before clinical criteria for Alzheimer's Disease diagnosis are met.

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

...